Chronic graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 9, Issue 4, 2003, Pages 215-233

  Lee, Stephanie J ^a   Vogelsang, Georgia ^b   Flowers, Mary E D ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Allogeneic stem cell transplantation; Chronic graft versus host disease

Indexed keywords

ACICLOVIR; AZATHIOPRINE; BUSULFAN; CALCINEURIN INHIBITOR; CLOFAZIMINE; CLOTRIMAZOLE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; ETRETIN; ETRETINATE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; INFLIXIMAB; MEASLES MUMPS RUBELLA VACCINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTRALIZING ANTIBODY; NYSTATIN; PREDNISONE; PSORALEN; RAPAMYCIN; STEROID; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALLOGENEIC STEM CELL TRANSPLANTATION; ANAPHYLAXIS; ANTIBIOTIC PROPHYLAXIS; ARTHRALGIA; AVASCULAR NECROSIS; BONE MARROW SUPPRESSION; BRAIN PSEUDOTUMOR; CATARACT; CHEILITIS; CHICKENPOX; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CONSTIPATION; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE CLASSIFICATION; DROWSINESS; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; EYE TOXICITY; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; GRAFT INFECTION; GRAFT VERSUS LEUKEMIA EFFECT; HEADACHE; HEPATITIS; HUMAN; HYPERLIPIDEMIA; HYPERPIGMENTATION; HYPERTENSION; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MEASLES; MONOTHERAPY; MUMPS; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OSTEOPOROSIS; PANCREATITIS; PANCYTOPENIA; PATHOGENESIS; PHOTOTOXICITY; PRURITUS; PSYCHOSIS; PUVA; QUALITY OF LIFE; REVIEW; RISK FACTOR; RUBELLA; SEIZURE; SERUM SICKNESS; SKIN BURNING SENSATION; SKIN CANCER; SKIN DISEASE; SKIN IRRITATION; SOMNOLENCE; SURVIVAL TIME; THROMBOCYTOPENIA; THRUSH; TREMOR; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VOMITING; WHOLE BODY RADIATION; XEROSIS;

EID: 0042118920     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2003.50026     Document Type: Article

References (162)

1. Gilman AL Schultz KR Treatment of chronic GVHD. Bone Marrow Transplant 26 2000 460-462.
2. Goerner M Gooley T Flowers ME et al. Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. Biol Blood Marrow Transplant 8 2002 47-56.
3. Lee SJ Klein JP Barrett AJ et al. Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse Blood 100 2002 406-414.
4. Socie G Stone JV Wingard JR. et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry N Engl J Med. 341 1999 14-21.
5. Syrjala KL Chapko MK Vitaliano PP et al. Recovery after allogeneic marrow transplantation: Prospective study of predictors of long-term physical and psychosocial functioning Bone Marrow Transplant 11 1993 319-327.
6. Duell T van Lint MT Ljungman P et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation Ann Intern Med. 126 1997 184-192.
7. Sutherland HJ Fyles GM Adams G et al. Quality of life following bone marrow transplantation: A comparison of patient reports with population norms Bone Marrow Transplant 19 1997 1129-1136.
8. Beschorner WE Tutschka PJ Santos GW. Chronic graft-versus-host disease in the rat radiation chimera. I. Clinical features, hematology, histology, and immunopathology in long-term chimeras Transplantation 33 1982 393-399.
9. Tutschka PJ Teasdall R Beschorner WE et al. Chronic graft-versus-host disease in the rat radiation chimera. II. Immunological evaluation in long-term chimeras Transplantation 34 1982 289-294.
10. Atkinson K Shulman HM Deeg HJ et al. Acute and chronic graft-versus-host disease in dogs given hemopoietic grafts from DLA-nonidentical littermates. Two distinct syndromes Am J Pathol 108 1982 196-205.
11. DeClerck Y Draper V Parkman R. Clonal analysis of murine graft-vs-host disease. II. Leukokines that stimulate fibroblast proliferation and collagen synthesis in graft-vs. host disease J Immunol. 136 1986 3549-3552.
12. Hamilton BL Parkman R. Acute and chronic graft-versus-host disease induced by minor histocompatibility antigens in mice Transplantation 36 1983 150-155.
13. Nonomura A Kono N Minato H et al. Diffuse biliary tract involvement mimicking primary sclerosing cholangitis in an experimental model of chronic graft-versus-host disease in mice Pathol Int. 48 1998 421-427.
14. Slayback DL Dobkins JA Harper JM et al. Genetic factors influencing the development of chronic graft-versus-host disease in a murine model Bone Marrow Transplant 26 2000 931-938.
15. Zhang Y McCormick LL Desai SR et al. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: Cutaneous cytokines, chemokines, and immune cell activation J Immunol. 168 2002 3088-3098.
16. Okamoto I Kohno K Tanimoto T et al. IL-18 prevents the development of chronic graft-versus-host disease in mice J Immunol 164 2000 6067-6074.
17. Reinherz EL Parkman R Rappeport J et al. Aberrations of suppressor T cells in human graft-versus-host disease N Engl J Med. 300 1979 1061-1068.
18. Lichtman AH Krenger W Ferrara JL. Cytokine networks. In: Ferrara JLM. Deeg HJ Burakoff SJ., eds. Graft-vs.-Host Disease. Second Edition 1997 179-218 : Marcel Dekker, Inc New York.
19. Aractingi S Chosidow O. Cutaneous graft-versus-host disease Arch Dermatol. 134 1998 602-612.
20. Ratanatharathorn V Ayash L Lazarus HM et al. Chronic graft-versus-host disease: Clinical manifestation and therapy Bone Marrow Transplant 28 2001 121-129.
21. Ochs LA Miller WJ Filipovich AH et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation Bone Marrow Transplant 13 1994 455-460.
22. Storek J Gooley T Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease Blood 90 1997 4705-4709.
23. Solano C Martinez C Brunet S et al. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT Bone Marrow Transplant 22 1998 1129-1135.
24. Vigorito AC Azevedo WM Marques JF et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies Bone Marrow Transplant 22 1998 1145-1151.
25. Scott MA Gandhi MK Jestice HK et al. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: A case controlled study Bone Marrow Transplant 22 1998 273-276.
26. Champlin RE Schmitz N Horowitz MM et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT) Blood 95 2000 3702-3709.
27. Snowden JA Nivison-Smith I Atkinson K et al. Allogeneic PBPC transplantation: An effect on incidence and distribution of chronic graft-versus-host disease without long-term survival benefit? Bone Marrow Transplant 25 2000 119-120.
28. Cutler C Giri S Jeyapalan S et al. Acute and chronic graft-versus-host disease after allogeneic peripheral- blood stem-cell and bone marrow transplantation: A meta-analysis J Clin Oncol 19 2001 3685-3691.
29. Morton J Hutchins C Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: Significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells Blood. 98 2001 3186-3191.
30. Collins RH Jr Shpilberg O Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol. 15 1997 433-444.
31. Dazzi F Szydlo RM Craddock C et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia Blood 95 2000 67-71.
32. Hess A Thoburn C Chen W et al. Autoreactive T-Cell subsets in acute and chronic syngeneic graft-versus- host disease Transplant Proc. 33 2001 1754-1756.
33. Sullivan KM Parkman R. The pathophysiology and treatment of graft-versus-host disease Clin Haematol 12 1983 775-789.
34. Weinberg K Blazar BR Wagner JE et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation Blood 97 2001 1458-1466.
35. Parkman R. Chronic graft-versus-host disease Curr Opin Hematol. 5 1998 22-25.
36. Rouquette-Gally AM Boyeldieu D Prost AC et al. Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients Transplantation 46 1988 238-240.
37. Aractingi S de The H Gluckman E et al. PML is expressed in chronic graft-versus-host disease lesions Bone Marrow Transplant 19 1997 1125-1128.
38. Soderberg C Sumitran-Karuppan S Ljungman P et al. CD13-specific autoimmunity in cytomegalovirus-infected immunocompromised patients Transplantation 61 1996 594-600.
39. Soderberg C Larsson S Rozell BL et al. Cytomegalovirus-induced CD13-specific autoimmunity-a possible cause of chronic graft-vs-host disease Transplantation 61 1996 600-609.
40. Barak V Levi-Schaffer F Nisman B et al. Cytokine dysregulation in chronic graft versus host disease Leuk Lymphoma. 17 1995 169-173.
41. Liem LM Fibbe WE van Houwelingen HC et al. Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus- host disease Transplantation 67 1999 59-65.
42. Korholz D Kunst D Hempel L et al. Decreased interleukin 10 and increased interferon-gamma production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation Bone Marrow Transplant 19 1997 691-695.
43. Nelson JL Furst DE Maloney S et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma Lancet 351 1998 559-562.
44. Evans PC Lambert N Maloney S et al. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma Blood 93 1999 2033-2037.
45. Storb R Prentice RL Sullivan KM et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA- identical siblings Ann Intern Med. 98 1983 461-466.
46. Bostrom L Ringden O Jacobsen N et al. A European multicenter study of chronic graft-versus-host disease. The role of cytomegalovirus serology in recipients and donors-acute graft- versus-host disease, and splenectomy Transplantation 49 1990 1100-1105.
47. Atkinson K Horowitz MM Gale RP et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation Blood 75 1990 2459-2464.
48. Ringden O Paulin T Lonnqvist B et al. An analysis of factors predisposing to chronic graft-versus-host disease Exp Hematol. 13 1985 1062-1067.
49. Carlens S Ringden O Remberger M et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis Bone Marrow Transplant 22 1998 755-761.
50. Przepiorka D Anderlini P Saliba R et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation Blood 98 2001 1695-1700.
51. Wagner JL Seidel K Boeckh M et al. De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival Biol Blood Marrow Transplant 6 2000 633-639.
52. Wagner JL Flowers ME Longton G et al. The development of chronic graft-versus-host disease: An analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation Bone Marrow Transplant 22 1998 139-146.
53. Remberger M Aschan J Lonnqvist B et al. An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation Transplant Proc. 33 2001 1769-1770.
54. Zaucha JM Gooley T Bensinger WI et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation Blood 98 2001 3221-3227.
55. Wagner JE Barker JN DeFor TE et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: Influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival Blood 100 2002 1611-1618.
56. Korbling M Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: Does the source of hematopoietic stem cells matter? Blood 98 2001 2900-2908.
57. Remberger M Ringden O Blau IW et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors Blood 98 2001 1739-1745.
58. Elmaagacli AH Basoglu S Peceny R et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia Blood 99 2002 1130-1135.
59. Socie G Clift RA Blaise D et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: Long-term follow-up of 4 randomized studies Blood 98 2001 3569-3574.
60. Ratanatharathorn V Nash RA Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation Blood 92 1998 2303-2314.
61. Atkinson K Downs K. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA- identical sibling bone marrow transplantation Bone Marrow Transplant 16 1995 755-758.
62. Sullivan KM Graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation 1999 515-536 : Blackwell Science, Inc Malden, MA
63. Shulman HM Sullivan KM Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients Am J Med. 69 1980 204-217.
64. Wingard JR Piantadosi S Vogelsang GB et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation Blood 74 1989 1428-1435.
65. Morton A Anasetti C Gooley T et al. Chronic graft-versus-host disease (GVHD) following unrelated donor transplantation Blood 90 1997 590A.
66. Akpek G Zahurak ML Piantadosi S et al. Development of a prognostic model for grading chronic graft-versus-host disease Blood 97 2001 1219-1226.
67. Arora M Burns LJ Davies SM et al. Chronic graft versus host disease: a prospective cohort study Biol Blood Marrow Transplant 9 2003 38-45.
68. Gaziev D Lucarelli G Polchi P et al. A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease Bone Marrow Transplant 27 2001 45-51.
69. Sullivan KM Agura E Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation Semin. Hematol. 28 1991 250-259.
70. Flowers ME Parker PM Johnston LJ et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial Blood 100 2002 415-419.
71. Graze PR Gale RP Chronic graft versus host disease: A syndrome of disordered immunity Am J Med. 66 1979 611-620.
72. Knobler HY Sagher U Peled IJ et al. Tolerance to donor-type skin in the recipient of a bone marrow allograft. Treatment of skin ulcers in chronic graft-versus-host disease with skin grafts from the bone marrow donor Transplantation 40 1985 223-225.
73. Hart DE Simko M Harris E. How to produce moisture chamber eyeglasses for the dry eye patient J Am Optom Assoc 65 1994 517-522.
74. Schubert MM Sullivan KM Morton TH et al. Oral manifestations of chronic graft-v-host disease Arch Intern Med 144 1984 1591-1595.
75. Nagler R Marmary Y Krausz Y et al. Major salivary gland dysfunction in human acute and chronic graft- versus-host disease (GVHD) Bone Marrow Transplant 17 1996 219-224.
76. Akpek G Valladares JL Lee L et al. Pancreatic insufficiency in patients with chronic graft-versus-host disease Bone Marrow Transplant 27 2001 163-166.
77. Zauner C Rabitsch W Schneeweiss B et al. Energy and substrate metabolism in patients with chronic extensive graft-versus-host disease Transplantation 71 2001 524-528.
78. Jacobsohn DA Margolis J Doherty J et al. Weight loss and malnutrition in patients with chronic graft-versus-host disease Bone Marrow Transplant 29 2002 231-236.
79. Strasser SI Shulman HM Flowers ME et al. Chronic graft-versus-host disease of the liver: Presentation as an acute hepatitis Hepatology 32 2000 1265-1271.
80. Arai S Lee LA Vogelsang GB. A systematic approach to hepatic complications in hematopoietic stem cell transplantation J Hematother Stem Cell Res 11 2002 215-229.
81. Rhodes DF Lee WM Wingard JR et al. Orthotopic liver transplantation for graft-versus-host disease following bone marrow transplantation Gastroenterology 99 1990 536-538.
82. Clark JG Crawford SW Madtes DK et al. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course Ann Intern Med 111 1989 368-376.
83. Sullivan KM Storek J Kopecky KJ et al. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: Clinical outcome and effect on subsequent immune recovery Biol Blood Marrow Transplant 2 1996 44-53.
84. Boas SR Noyes BE Kurland G et al. Pediatric lung transplantation for graft-versus-host disease following bone marrow transplantation Chest 105 1994 1584-1586.
85. Holland HK Wingard JR Beschorner WE et al. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG Blood 72 1988 621-627.
86. Philit F Wiesendanger T Archimbaud E et al. Post-transplant obstructive lung disease ("bronchiolitis obliterans"): A clinical comparative study of bone marrow and lung transplant patients Eur Respir J 8 1995 551-558.
87. Janin A Socie G Devergie A et al. Fasciitis in chronic graft-versus-host disease. A clinicopathologic study of 14 cases Ann Intern Med 120 1994 993-998.
88. Sullivan KM Witherspoon RP Storb R et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease Blood 72 1988 555-561.
89. Anasetti C Rybka W Sullivan KM et al. Graft-v-host disease is associated with autoimmune-like thrombocytopenia Blood 73 1989 1054-1058.
90. Siadak M Sullivan KM. The management of chronic graft-versus-host disease Blood Rev 8 1994 154-160.
91. Storek J Witherspoon RP Webb D et al. Lack of B cells precursors in marrow transplant recipients with chronic graft-versus-host disease Am J Hematol 52 1996 82-89.
92. Sherer Y Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation Bone Marrow Transplant 22 1998 873-881.
93. Maury S Mary JY Rabian C et al. Prolonged immune deficiency following allogeneic stem cell transplantation: Risk factors and complications in adult patients Br J Haematol 115 2001 630-641.
94. Kulkarni S Powles R Treleaven J et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants Blood 95 2000 3683-3686.
95. Jacobsohn DA Montross S Anders V et al. Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease Bone Marrow Transplant 28 2001 1047-1051.
96. Kurtzberg J Laughlin M Graham ML et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients N Engl J Med 335 1996 157-166.
97. Gluckman E Rocha V Boyer-Chammard A et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group N Engl J Med 337 1997 373-381.
98. Sullivan KM Witherspoon RP Storb R et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation Blood 72 1988 546-554.
99. Loughran TP Jr Sullivan K Morton T et al. Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation Blood 76 1990 228-234.
100. Centers for Disease Control, Infectious Disease Society of America, American Society for Blood and Marrow Transplantation Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients Biol Blood Marrow Transplant 6 2000 659-727.
101. Vogelsang GB. How I treat chronic graft-versus-host disease Blood 97 2001 1196-1201.
102. Flowers MED. Traditional treatment of chronic graft-versus-host disease Blood Marrow Transplant Rev. 12 2002 5-8.
103. Koc S Leisenring W Flowers MED et al. Therapy for chronic graft-versus-host disease: A randomized trial comparing cyclosporine plus prednisone versus prednisone alone Blood 100 2002 48-51.
104. Parker PM Chao N Nademanee A et al. Thalidomide as salvage therapy for chronic graft-versus-host disease Blood 86 1995 3604-3609.
105. Browne PV Weisdorf DJ DeFor T et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease Bone Marrow Transplant 26 2000 865-869.
106. Vogelsang GB Farmer ER Hess AD et al. Thalidomide for the treatment of chronic graft-versus-host disease N Engl J Med 326 1992 1055-1058.
107. Weiden PL Sullivan KM Flournoy N et al. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation N Engl J Med 304 1981 1529-1533.
108. Deeg HJ Leisenring W Storb R et al. Long-term outcome after marrow transplantation for severe aplastic anemia Blood 91 1998 3637-3645.
109. Weiden PL Flournoy N Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts N Engl J Med 300 1979 1068-1073.
110. Sullivan KM Weiden PL Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia [published erratum appears in Blood 1989;74:1180] Blood 73 1989 1720-1728.
111. Horowitz MM Gale RP Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation Blood 75 1990 555-562.
112. Ringden O Labopin M Gluckman E et al. Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. The Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Transplant Proc. 29 1997 733-734.
113. Brunet S Urbano-Ispizua A Ojeda E et al. Favourable effect of the combination of acute and chronic graft-versus- host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies Br J Haematol 114 2001 544-550
114. Pichert G Roy DC Gonin R et al. Distinct patterns of minimal residual disease associated with graft- versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia J Clin Oncol 13 1995 1704-1713.
115. Chiodi S Spinelli S Ravera G et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation Br J Haematol 110 2000 614-619.
116. Heinonen H Volin L Uutela A et al. Quality of life and factors related to perceived satisfaction with quality of life after allogeneic bone marrow transplantation Ann Hematol 80 2001 137-143.
117. Lee S Cook EF Soiffer R et al. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease Biol Blood Marrow Transplant 8 2002 444-452.
118. Schmidt GM Niland JC Forman SJ et al. Extended follow-up in 212 long-term allogeneic bone marrow transplant survivors. Issues of quality of life Transplantation 55 1993 551-557.
119. Wingard JR Curbow B Baker F et al. Health, functional status, and employment of adult survivors of bone marrow transplantation Ann Intern Med 114 1991 113-118.
120. Andrykowski MA Greiner CB Altmaier EM et al. Quality of life following bone marrow transplantation: Findings from a multicentre study Br J Cancer 71 1995 1322-1329.
121. Marks DI Gale DJ Vedhara K et al. A quality of life study in 20 adult long-term survivors of unrelated donor bone marrow transplantation Bone Marrow Transplant 24 1999 191-195.
122. Socie G Mary JY Esperou H et al. Health and functional status of adult recipients 1 year after allogeneic haematopoietic stem cell transplantation Br J Haematol 113 2001 194-201.
123. Chao NJ Parker PM Niland JC et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease Biol Blood Marrow Transplant 2 1996 86-92.
124. Kansu E Gooley T Flowers ME et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: A prospective randomized clinical trial Blood 98 2001 3868-3870.
125. Deeg HJ Lin D Leisenring W et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial Blood 89 1997 3880-3887.
126. Storb R Deeg HJ Pepe M et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial [see comments] Br J Haematol 72 1989 567-572.
127. Storb R Deeg HJ Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial Blood 73 1989 1729-1734.
128. Storb R Pepe M Anasetti C et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 76 1990 1037-1045.
129. Ross M Schmidt GM Niland JC et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: Effect on chronic graft-vs.-host disease and long-term survival Biol Blood Marrow Transplant 5 1999 285-291.
130. Bacigalupo A Van Lint MT Occhini D et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia Blood 77 1991 1423-1428.
131. Storb R Leisenring W Anasetti C et al. Methotrexate and cyclosporine for graft-vs.-host disease prevention: What length of therapy with cyclosporine? Biol Blood Marrow Transplant 3 1997 194-201.
132. Winston DJ Antin JH Wolff SN et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation Bone Marrow Transplant 28 2001 187-196.
133. Sullivan KM Shulman HM Storb R et al. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression Blood 57 1981 267-276.
134. Arora M Wagner JE Davies SM et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft- versus-host disease Biol Blood Marrow Transplant 7 2001 265-273.
135. Koc S Leisenring W Flowers ME et al. Thalidomide for treatment of patients with chronic graft-versus-host disease Blood 96 2000 3995-3996.
136. Akpek G Lee SM Anders V et al. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease Biol Blood Marrow Transplant 7 2001 495-502.
137. Tzakis AG Abu-Elmagd K Fung JJ et al. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation Transplant Proc 23 1991 3225-3227.
138. Carnevale-Schianca F Martin P Sullivan K et al. Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease Biol Blood Marrow Transplant 6 2000 613-620.
139. Basara N Blau WI Romer E et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients Bone Marrow Transplant 22 1998 61-65.
140. Mookerjee B Altomonte V Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus Bone Marrow Transplant 24 1999 517-520.
141. Dall'Amico R Rossetti F Zulian F et al. Photopheresis in paediatric patients with drug-resistant chronic graft- versus-host disease Br J Haematol 97 1997 848-854.
142. Greinix HT Volc-Platzer B Rabitsch W et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease Blood 92 1998 3098-3104.
143. Child FJ Ratnavel R Watkins P et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft- versus-host disease (GVHD) Bone Marrow Transplant 23 1999 881-887.
144. Alcindor T Gorgun G Miller KB et al. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease Blood 98 2001 1622-1625.
145. Eppinger T Ehninger G Steinert M et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease Transplantation 50 1990 807-811.
146. Jampel RM Farmer ER Vogelsang GB et al. PUVA therapy for chronic cutaneous graft-vs-host disease Arch Dermatol 127 1991 1673-1678.
147. Kapoor N Pelligrini AE Copelan EA et al. Psoralen plus ultraviolet A (PUVA) in the treatment of chronic graft versus host disease: preliminary experience in standard treatment resistant patients Semin Hematol 29 1992 108-112.
148. Vogelsang GB Wolff D Altomonte V et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA) Bone Marrow Transplant 17 1996 1061-1067.
149. Redding SW Callander NS Haveman CW et al. Treatment of oral chronic graft-versus-host disease with PUVA therapy: Case report and literature review Oral Surg Oral Med Oral Pathol Oral Radiol Endod 86 1998 183-187.
150. Enk CD Elad S Vexler A et al. Chronic graft-versus-host disease treated with UVB phototherapy Bone Marrow Transplant 22 1998 1179-1183.
151. Rovelli A Arrigo C Nesi F et al. The role of thalidomide in the treatment of refractory chronic graft- versus-host disease following bone marrow transplantation in children Bone Marrow Transplant 21 1998 577-581.
152. Marcellus DC Altomonte VL Farmer ER et al. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease Blood 93 1999 66-70.
153. Gilman AL Chan KW Mogul A et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease Biol Blood Marrow Transplant 6 2000 327-334..
154. Fried RH Murakami CS Fisher LD et al. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver Ann Intern Med 116 1992 624-629.
155. Lee SJ Wegner SA McGarigle CJ et al. Treatment of chronic graft-versus-host disease with clofazimine Blood 89 1997 2298-2302.
156. Ratanatharathorn V Carson E Reynolds C et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune- mediated thrombocytopenia in a patient with chronic graft-versus-host disease Ann Intern Med 133 2000 275-279.
157. Socie G Gevergie A Cosset JM et al. Low-dose (one gray) total-lymphoid irradiation for extensive, drug- resistant chronic graft-versus-host disease Transplantation 49 1990 657-658.
158. Bullorsky EO Shanley CM Stemmelin GR et al. Total lymphoid irradiation for treatment of drug resistant chronic GVHD Bone Marrow Transplant 11 1993 75-76.
159. Epstein JB Nantel S Sheoltch SM. Topical azathioprine in the combined treatment of chronic oral graft-versus-host disease Bone Marrow Transplant 25 2000 683-687.
160. Aoyama H Tabata N Tanaka M et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment Br J Dermatol 133 1995 494-496.
161. Kiang E Tesavibul N Yee R et al. The use of topical cyclosporin A in ocular graft-versus-host-disease Bone Marrow Transplant 22 1998 147-151.
162. Voltarelli JC Ahmed H Paton EJ et al. Beneficial effect of intravenous lidocaine in cutaneous chronic graft-versus-host disease secondary to donor lymphocyte infusion Bone Marrow Transplant 28 2001 97-99.